A- A A+

Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial. 

Marseille E, Mitchell JM, Kahn JG (2022) 

PLoS ONE 17(2): e0263252. doi.org/10.1371/journal.pone.0263252

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0263252